Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010

BMC Infectious Diseases

Hyun Ok Kim¹  Hyuk Ki Min²  Quehn Park³  Moon Jung Kim¹ 

[1] Department of Laboratory Medicine, Yonsei University, College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea;Blood Services Headquarters, Korean Red Cross, Seoul, South Korea;Chung-Ang University Hospital, Seoul, South Korea

关键词: Donor screening test;    Blood safety;    Transfusion-transmitted infection;    Residual risk;   

Others  :  1175331
DOI  :  10.1186/1471-2334-12-160

 received in 2012-02-23, accepted in 2012-07-05,  发布年份 2012

【 摘 要 】

Background

Despite screening blood donations with advanced technologies and improved donor screening, the risk of transfusion-transmitted infections persists. This risk is mainly due to blood donations collected during the window period. A precise estimate of the transfusion risk of viral infection will help to determine the effect of new and current safety measures and to prioritize and allocate limited resources. Therefore, we estimated the risk of transfusion-transmitted viral infection in blood donations collected in Korea from 2000 to 2010.

Methods

Blood donations collected at 16 blood centers were tested for HIV, HCV, and HBV to estimate the residual risk of transfusion-transmitted viral infection. The residual risk was calculated in two-year periods using the incidence/window model. The incidence rates for HIV/HCV and the confirmed positive rate for HIV/HCV in first-time and repeat donors were compared.

Results

The residual risks for HIV in 2004/2005 and 2009/2010 were 1 in 1,080,244 and 1 in 1,356,547, respectively. The risks for HCV in 2000/2001 and 2009/2010 were 1 in 81,431 and 1 in 2,984,415, and the risks for HBV in 2000/2001 and 2009/2010 were 1 in 45,891 and 1 in 43,666. These estimates indicate that the residual risks for HCV in Korea have declined 36.6-fold, and those for HIV and HBV have not improved significantly, compared to previous estimates. The odds ratios for HCV and HBV positivity in first-time donors compared to repeat donors were 11.8 and 19.6, respectively.

Conclusions

The residual risk of HCV declined over the last decade due to improved screening reagents, implementation of the nucleic acid amplification test, and tight application of strict donor selection procedures. Current residual risk estimates for HIV and HCV in Korea are extremely low, but the risk for HBV is still high; therefore, urgent measures should focus on decreasing the residual risk of HBV. Despite the introduction of more sensitive assays in blood screening, several other factors may influence the actual residual risk of transfusion-transmitted infection. A continuous monitoring of residual risk of transfusion-transmitted infection is crucial in managing blood safety.

【 授权许可】

   
2012 Kim et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kim MJ, Park Q, Seo DH, Lee KN: Residual risk of transfusion-transmitted virus infection among blood donors. Korean J Blood Transfus 2006, 17(Suppl):117.
• [2]Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334(26):1685-1690.
• [3]Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, Read S, Dodd RY, Petersen LR: Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995, 35(2):91-97.
• [4]Mimms LT, Mosley JW, Hollinger FB, Aach RD, Stevens CE, Cunningham M, Vallari DV, Barbosa LH, Nemo GJ: Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993, 307(6912):1095-1097.
• [5]Comanor L, Holland P: Hepatitis B virus blood screening: unfinished agendas. Vox sanguinis 2006, 91(1):1-12.
• [6]Courouce AM, Pillonel J: Estimation of risk of virus transmission in hepatitis B and C and human retrovirus via transfusion of labile blood derivatives. Transfus Clinique et Biologique : J de la Societe Francaise de Transfusion Sanguine 1996, 3(1):13-18.
• [7]Dodd RY: Notari EPt, Stramer SL: Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002, 42(8):975-979.
• [8]Lelie PN, Cuypers HT, Reesink HW, van der Poel CL, Winkel I, Bakker E, van Exel-Oehlers PJ, Vallari D, Allain JP, Mimms L: Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays. J Med Virol 1992, 37(3):203-209.
• [9]Kim M, Park Q: The hepatitis B virus surface antigen prevalence among Korean blood donors. Korean J Blood Transfus 2011, 22:189-197.
• [10]Zou S, Stramer SL, Notari EP, Kuhns MC, Krysztof D, Musavi F, Fang CT, Dodd RY: Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009, 49(8):1609-1620.
• [11]Weusten JJ, van Drimmelen HA, Lelie PN: Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002, 42(5):537-548.
• [12]Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ, Keller AJ: Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002, 42(10):1365-1372.
• [13]Pillonel J, Laperche S, Saura C, Desenclos JC, Courouce AM: Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 2002, 42(8):980-988.
• [14]Alvarez M, Oyonarte S, Rodriguez PM, Hernandez JM: Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion 2002, 42(8):994-998.
• [15]O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC: Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007, 47(2):316-325.
• [16]Pillonel J, Barin F, Laperche S, Bernillon P, Le Vu S, Brunet S, Thierry D, Desenclos JC: Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 through 2006: use of an immunoassay to identify recent infections. Transfusion 2008, 48(8):1567-1575.
• [17]Zuckerman A: Hepatitis Viruses. In Medical Microbiology. 4th edition. Edited by Baron S. Galveston: The University of Texas Branch at Galveston; 1996:849-863.
• [18]Brant LJ, Reynolds C, Byrne L, Davison KL: Hepatitis B and residual risk of infection in English and Welsh blood donors, 1996 through 2008. Transfusion 2011, 51(7):1493-1502.
• [19]Maresch C, Schluter PJ, Wilson AD, Sleigh A: Residual infectious disease risk in screened blood transfusion from a high-prevalence population: Santa Catarina, Brazil. Transfusion 2008, 48(2):273-281.
• [20]Otsubo H, Yamaguchi K: Current risks in blood transfusion in Japan. Jpn J Infect Dis 2008, 61(6):427-433.
• [21]Oh HB, Whang GK, Kim SI: Seroincidence of hepatitis B virus among Korean blood donors. Korean Soc Blood Transfus 1999, 10(1):1-4.
• [22]Gonzalez R, Echevarria JM, Avellon A, Barea L, Castro E: Acute hepatitis B virus window-period blood donations detected by individual-donation nucleic acid testing: a report on the first two cases found and interdicted in Spain. Transfusion 2006, 46(7):1138-1142.
• [23]Sabino EC, Goncalez TT, Carneiro-Proietti AB, Sarr M, Ferreira JE, Sampaio DA, Salles NA, Wright DJ, Custer B, Busch M: Human immunodeficiency virus prevalence, incidence, and residual risk of transmission by transfusions at Retrovirus Epidemiology Donor Study-II blood centers in Brazil. Transfusion 2011, 52(4):870-879.
• [24]Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993, 341(8859):1501-1504.
• [25]Ling AE, Robbins KE, Brown TM, Dunmire V, Thoe SY, Wong SY, Leo YS, Teo D, Gallarda J, Phelps B, et al.: Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000, 284(2):210-214.
• [26]Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, Di Bisceglie AM, Shih JW, Neuwald PD: Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepat 1995, 2(3):121-132.
• [27]Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH, Group N-RNS: A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005, 45(2):254-264.
• [28]Hepatitis BCountries or areas at risk http://gamapserver.who.int/mapLibrary/Files/Maps/Global_HepB_ITHRiskMap.png webcite
• [29]Statistic KH: Kora National Health and Nutrition Examination Survey (KNHANES V-1). In: Ministry of Health and Welfare, Korea Center for Disease Control and Prevention; 2010:2011.
• [30]Kim H, Hur M, Moon HW, Park CM, Cho JH, Park KS, Lee K, Chang S: Pre- and post-transfusion testing for hepatitis B virus surface antigen and antibody in blood recipients: a single-institution experience in an area of high endemicity. Ann Lab Med 2012, 32(1):73-78.